FDA approves first mRNA influenza vaccine as regional vaccination efforts expand

The U.S. Food and Drug Administration (FDA) has approved the first mRNA-based influenza vaccine, manufactured by Moderna. Specifically approved for adults aged 50 to 64, the vaccine, named mFLUSIVA, utilizes genetic code to instruct the body to produce viral proteins, triggering an immune response. This technology allows for faster production and updates compared to traditional egg-based or cell-based vaccines.

In Hong Kong, the Department of Health has announced the 2026/27 influenza vaccination program will begin on September 17. The government has procured 1.6 million doses, including an increase in the “Doctor Vaccine Procurement Pilot Scheme” from 100,000 to 300,000 doses. To improve efficiency, the school outreach program will introduce electronic consent forms via the “eHealth” platform.

Health officials in Hong Kong noted that while vaccination rates for some groups have risen, rates for children aged 6 months to 2 years remain low at 27.5%, and rates for seniors over 65 have seen a slight decline. The CDC in the United States recommends that most people aged 6 months and older receive their flu shots between September and October to ensure protection during the peak season.